September 11, 2024 12:59 AM EDT
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 9, 2024 5:00 PM EDT
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
September 9, 2024 7:00 AM EDT
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
August 26, 2024 7:00 AM EDT
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
August 26, 2024 1:00 AM EDT
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 20, 2024 6:45 PM EDT
Regeneron Provides Update on Biologics License Application for Linvoseltamab
August 7, 2024 4:05 PM EDT
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
August 1, 2024 6:30 AM EDT
Regeneron Reports Second Quarter 2024 Financial and Operating Results
July 31, 2024 7:30 AM EDT
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
July 3, 2024 1:00 AM EDT